China Biotech Services Holdings Ltd. has announced a memorandum of understanding in collaboration with AXA China Region Insurance Company (Bermuda) Limited, AXA International Reinsurance (Shanghai) Company Limited, Qianhai Reinsurance Co., Ltd., and Arthur J. Gallagher (Singapore) Pte. Ltd. This partnership focuses on the development of a BNCT medical insurance product, underscoring their commitment to advancing BNCT treatment and improving patient outcomes globally. The agreement is still subject to further negotiations, with no assurance of the signing of definitive agreements. Shareholders and potential investors are advised to exercise caution in dealing with the company's shares.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.